• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Nicaise Claude

    3/31/26 4:02:06 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMMB alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Nicaise Claude

    (Last)(First)(Middle)
    C/O CHEMOMAB THERAPEUTICS LTD.
    10 HABARZEL STBUILDING C, 10TH FLOOR

    (Street)
    TEL AVIV6158101

    (City)(State)(Zip)

    ISRAEL

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    Chemomab Therapeutics Ltd. [ CMMB ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock option (right to buy American Depositary Shares) (1)04/19/2031American Depositary Shares2,971$109.04D
    Stock option (right to buy American Depositary Shares) (2)03/07/2032American Depositary Shares1,705$14.12D
    Stock option (right to buy American Depositary Shares) (3)03/21/2033American Depositary Shares1,714$6.48D
    Stock option (right to buy American Depositary Shares) (4)03/18/2034American Depositary Shares2,520$2.96D
    Stock option (right to buy American Depositary Shares) (5)03/16/2035American Depositary Shares3,821$6.16D
    Stock option (right to buy American Depositary Shares)03/16/202703/16/2036American Depositary Shares5,172$2.14D
    Explanation of Responses:
    1. The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
    2. The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
    3. The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
    4. The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.
    5. The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.
    Remarks:
    This Form 3 has been filed after March 18, 2026 but prior to April 20, 2026 in reliance on the temporary relief made available to the directors and officers of certain foreign private issuers by the Staff of the Securities and Exchange Commission in its no-action letter dated March 13, 2026.
    /s/ Claude Nicaise03/27/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $CMMB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMMB

    DatePrice TargetRatingAnalyst
    5/13/2024$4.00Buy
    Maxim Group
    5/6/2024$6.00Perform → Outperform
    Oppenheimer
    12/19/2023$7.00Buy
    ROTH MKM
    3/10/2022$30.00 → $20.00Outperform
    Oppenheimer
    12/7/2021$30.00Buy
    Aegis Capital
    More analyst ratings

    $CMMB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

    TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The corporate presentation will be webcast live and will be available at the investor relations section of the Chemomab website for 90 days. Oppenheimer 36th Annual Healthcare Life Sciences Confere

    2/17/26 8:00:00 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

    —New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial— TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis (PSC) were published in the current issue of the American Journal of Gastroenterology.1 The study showed that nebokitug was generally safe and w

    12/2/25 8:00:00 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

    TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofitel Hotel in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1-on-1 investor meetings with companies working in the rare disease space. Dr. Mor will present a corporate overview and will be available for one-on-one meetings with registered attendee

    11/24/25 8:00:00 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Quigley Jill M.

    3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

    3/31/26 4:03:22 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Nicaise Claude

    3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

    3/31/26 4:02:06 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Darvish Nissim

    4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

    7/5/23 5:48:43 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMMB
    SEC Filings

    View All

    $CMMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 20-F filed by Chemomab Therapeutics Ltd.

    20-F - Chemomab Therapeutics Ltd. (0001534248) (Filer)

    3/23/26 4:07:51 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Chemomab Therapeutics Ltd.

    6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

    3/20/26 4:05:20 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Chemomab Therapeutics Ltd.

    6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

    3/19/26 8:05:05 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Chemomab Therapeutics with a new price target

    Maxim Group initiated coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $4.00

    5/13/24 8:28:18 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chemomab Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Chemomab Therapeutics from Perform to Outperform and set a new price target of $6.00

    5/6/24 7:45:06 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM resumed coverage on Chemomab Therapeutics with a new price target

    ROTH MKM resumed coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $7.00

    12/19/23 6:47:13 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMMB
    Leadership Updates

    Live Leadership Updates

    View All

    Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy

    TEL AVIV, Israel, Nov. 30, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Mitchell L. Jones, MD, PhD, as Vice President of Corporate Development & Strategy. Dr. Jones brings Chemomab more than 15 years of leadership experience in biopharmaceutical research, clinical development, corporate strategy and entrepreneurship, organizational development and team-building, technology transfer and licensing and acquisitions. He will be responsible for spearheading the corpor

    11/30/22 7:00:00 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chemomab Announces Appointment of Matthew Frankel, MD, MBA as Chief Medical Officer

    TEL AVIV, Israel, Nov. 14, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Matthew Frankel, MD, MBA as Chief Medical Officer (CMO) and Vice President of Drug Development. "We believe Dr. Frankel's wealth of experience across all aspects of clinical development and medical affairs, along with his outstanding performance in helping to bring biologic and

    11/14/22 7:00:00 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities

    ─Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President  of Clinical Development─ TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development. "Ch

    8/12/22 6:00:00 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMMB
    Financials

    Live finance-specific insights

    View All

    Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

    TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd.                                                     

    10/30/24 7:00:00 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

    TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company

    8/12/24 7:00:00 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

    First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC), Establishing Clinical Proof-of-Concept for the Disease-Modifying Potential of CM-101 Treatment with CM-101 Led to Statistically Significant Improvements in Liver Stiffness, a Well-Validated Biomarker of Disease Progression in PSC Treatment with CM-101 Led to Statistically Significant Improvements in Pruritis and Improvements in Total Bilirubin and Liver Function Tests Positive Phase 2 Data Paves Way f

    7/25/24 7:00:00 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

    SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/29/24 3:04:59 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Chemomab Therapeutics Ltd.

    SC 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/21/24 10:59:28 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

    SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    9/16/24 4:34:03 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care